肠道病毒属感染对肝癌患者有益
研究对2647名受试者进行全病毒血清抗体谱分析,发现肝癌患者对153种病毒抗原的血清反应显著低于健康人,且对其中抗原反应高与慢性肝病和肝癌患者临床结局较好相关。39%反应性抗原共享表位CE1,可诱导CD4+和CD8+ T细胞活化及CD8+ T细胞介导的肝癌细胞杀伤。
要点
- 肝癌患者对153种病毒抗原的血清反应显著低于健康人。
- 对153种病毒抗原血清反应较高与慢性肝病和肝癌患者临床结局较好相关。
- 表位CE1可诱导CD4+和CD8+ T细胞活化及CD8+ T细胞介导的肝癌细胞杀伤。
核心结论
- 过去暴露于肠道病毒属成员可能对癌症患者有益,提示基于病毒肽的肝癌疫苗潜力。
研究设计与样本
- 使用微生物噬菌体文库对2647名研究对象进行全病毒血清抗体谱分析,并检测选择性病毒抗原对健康人和肝癌患者血液免疫细胞的生物学活性。
主要发现
- 肝癌患者对153种病毒抗原的血清反应显著低于健康人。
- 对153种病毒抗原血清反应较高与慢性肝病和肝癌患者临床结局较好相关,且该发现在性别、种族和病因不同的人群中一致。
- 39%的反应性病毒抗原共享表位CE1,属于鼻病毒和肠道病毒家族。
- CE1可诱导CD4+和CD8+ T细胞活化及CD8+ T细胞介导的肝癌细胞杀伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatocellular carcinoma (HCC) is a significant global cancer burden, with rising incidence and lacking a unified prevention strategy due to complex aetiologies. Viral exposures may shape host immunity via specific reactive viral antigens that could induce immune responses against hepatocarcinogenesis. OBJECTIVE: We aimed to characterise viral exposure differences between HCC patients and healthy individuals and identify potentially protective viral antigens against HCC. DESIGN: We profiled pan-viral serological antibody repertoires using a microbial phage library among 2647 study subjects and examined the biological activities of selective viral antigens on blood-derived immune cells from both healthy individuals and HCC patients. RESULT: We identified 153 viral antigens with a significantly reduced serological response in HCC patients compared with healthy individuals. We also observed that a higher serological response to 153 viral antigens is associated with better clinical outcomes of patients with chronic liver diseases and HCC. These findings are consistent across different populations across sex, ethnicity and aetiology. We identified a common epitope (CE1) shared among 39% of reactive viral antigens that belong to the rhinovirus and enterovirus families. We demonstrated that CE1 could induce both CD4+ and CD8+ T-cell activation and CD8+ T-cell-mediated HCC cell killing. CONCLUSIONS: Our results suggest that past exposures to members of the Enterovirus genus may be advantageous for cancer patients, highlighting the potential for a viral peptide-based HCC vaccine.
引用
- Ma L, Hung MH, Rashidi Mehrabadi F, et al. Beneficial infections of the enterovirus genus in patients with liver cancer. Gut. 2025. PMID: 40345802. doi:10.1136/gutjnl-2024-334681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。